These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 38863037

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. BUB1 Inhibition Sensitizes TNBC Cell Lines to Chemotherapy and Radiotherapy.
    Sriramulu S, Thoidingjam S, Siddiqui F, Brown SL, Movsas B, Walker E, Nyati S.
    Biomolecules; 2024 May 25; 14(6):. PubMed ID: 38927028
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A common Chk1-dependent phenotype of DNA double-strand break suppression in two distinct radioresistant cancer types.
    Dinkelborg PH, Wang M, Gheorghiu L, Gurski JM, Hong TS, Benes CH, Juric D, Jimenez RB, Borgmann K, Willers H.
    Breast Cancer Res Treat; 2019 Apr 25; 174(3):605-613. PubMed ID: 30607635
    [Abstract] [Full Text] [Related]

  • 7. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.
    Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA.
    BMC Cancer; 2015 Mar 03; 15():89. PubMed ID: 25884663
    [Abstract] [Full Text] [Related]

  • 8. Regorafenib sensitizes human breast cancer cells to radiation by inhibiting multiple kinases and inducing DNA damage.
    Mehta M, Griffith J, Panneerselvam J, Babu A, Mani J, Herman T, Ramesh R, Munshi A.
    Int J Radiat Biol; 2021 Mar 03; 97(8):1109-1120. PubMed ID: 32052681
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Maternal Embryonic Leucine Zipper Kinase (MELK) as a Novel Mediator and Biomarker of Radioresistance in Human Breast Cancer.
    Speers C, Zhao SG, Kothari V, Santola A, Liu M, Wilder-Romans K, Evans J, Batra N, Bartelink H, Hayes DF, Lawrence TS, Brown PH, Pierce LJ, Feng FY.
    Clin Cancer Res; 2016 Dec 01; 22(23):5864-5875. PubMed ID: 27225691
    [Abstract] [Full Text] [Related]

  • 11. CPNE1 predicts poor prognosis and promotes tumorigenesis and radioresistance via the AKT singling pathway in triple-negative breast cancer.
    Shao Z, Ma X, Zhang Y, Sun Y, Lv W, He K, Xia R, Wang P, Gao X.
    Mol Carcinog; 2020 May 01; 59(5):533-544. PubMed ID: 32181526
    [Abstract] [Full Text] [Related]

  • 12. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
    Tu X, Kahila MM, Zhou Q, Yu J, Kalari KR, Wang L, Harmsen WS, Yuan J, Boughey JC, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.
    Mol Cancer Ther; 2018 Nov 01; 17(11):2462-2472. PubMed ID: 30166399
    [Abstract] [Full Text] [Related]

  • 13. Radiosensitizing effect of a novel CTSS inhibitor by enhancing BRCA1 protein stability in triple-negative breast cancer cells.
    Choi E, Jeon KH, Lee H, Mun GI, Kim JA, Shin JH, Kwon Y, Na Y, Lee YS.
    Cancer Sci; 2024 Jun 01; 115(6):2036-2048. PubMed ID: 38613358
    [Abstract] [Full Text] [Related]

  • 14. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
    Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K.
    Breast Cancer Res; 2019 Sep 06; 21(1):104. PubMed ID: 31492187
    [Abstract] [Full Text] [Related]

  • 15. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
    Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.
    Breast Cancer Res; 2012 Jul 19; 14(4):R109. PubMed ID: 22812567
    [Abstract] [Full Text] [Related]

  • 16. Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition.
    Zhang H, Cohen AL, Krishnakumar S, Wapnir IL, Veeriah S, Deng G, Coram MA, Piskun CM, Longacre TA, Herrler M, Frimannsson DO, Telli ML, Dirbas FM, Matin AC, Dairkee SH, Larijani B, Glinsky GV, Bild AH, Jeffrey SS.
    Breast Cancer Res; 2014 Apr 07; 16(2):R36. PubMed ID: 24708766
    [Abstract] [Full Text] [Related]

  • 17. EP300 knockdown reduces cancer stem cell phenotype, tumor growth and metastasis in triple negative breast cancer.
    Ring A, Kaur P, Lang JE.
    BMC Cancer; 2020 Nov 10; 20(1):1076. PubMed ID: 33167919
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
    Mehta M, Basalingappa K, Griffith JN, Andrade D, Babu A, Amreddy N, Muralidharan R, Gorospe M, Herman T, Ding WQ, Ramesh R, Munshi A.
    Oncotarget; 2016 Oct 04; 7(40):64820-64835. PubMed ID: 27588488
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.